PReCePT was developed by the West of England AHSN in collaboration with University Hospitals Bristol NHS Foundation Trust, and involving both patients and staff. This evidence-based, cost-effective project has been designed to help reduce cerebral palsy in babies through increased antenatal administration of magnesium sulphate (MgSO4) to mothers during preterm labour, at cost of £1 per individual dose.
The intervention has been adopted by all five maternity units in the West of England, and projection modelling indicates that since the launch of the project in August 2014, phase one of PReCePT has prevented seven cases of cerebral palsy across the region, representing potential lifetime savings in the region of £5.1 million (as of February 2017).
Giving pre-term babies the best life chances
Growing numbers of pregnant women in pre-term labour are having an injection of magnesium sulphate to give their babies the best life chances. This is one family’s story. Through an initiative called PReCePT – preventing cerebral palsy in pre-term babies – all of England’s maternity units are now offering magnesium sulphate thanks to Academic Health Science Networks working with Patient Safety Collaboratives.
The Oxford Academic Health Science Network is a partnership of NHS providers, commissioners, universities and life science companies working together to improve health and prosperity in Berkshire, Buckinghamshire, Milton Keynes and Oxfordshire.
Health Innovation Network
Elly Salisbury was one of the first mothers to receive magnesium sulphate during preterm labour to reduce the chances of her babies developing cerebral palsy. Here she tells her story and explains why she is keen to support the PReCePT programme, which the AHSN Network is now rolling out across England. PReCePT aims to ensure at least 85% of all eligible mothers are receiving magnesium sulphate across all maternity hospitals in England by 2020. Find out more at ahsnnetwork.com/precept
PReCePT, which stands for the Prevention of Cerebral Palsy in PreTerm Labour, has been designed to help reduce cerebral palsy in babies by administering magnesium sulphate (MgSO4) to mothers during preterm labour, at a cost of around £1 per individual dose.
Preterm birth is the leading cause of brain injury and cerebral palsy, which has a lifelong impact on children and families.
The Eastern Academic Health Science Network